Filgrastim

Source: Wikipedia, the free encyclopedia.
Not to be confused with granulocyte-macrophage colony-stimulating factor or epoetin alfa.

Filgrastim
Clinical data
Trade namesNeupogen, others
Other namesXM02
Biosimilarsfilgrastim-aafi, filgrastim-sndz, filgrastim-ayow, Accofil, Biograstim, Fraven Grastofil, Nivestim,[1] Nivestym,[2] Nypozi, [3] Ratiograstim, Releuko,[4] Tevagrastim, Zarxio,[5] Zarzio[6]
AHFS/Drugs.comMonograph
MedlinePlusa692033
License data
Pregnancy
category
subcutaneous
Drug classHematopoietic agents, colony-stimulating factors
ATC code
Legal status
Legal status
Identifiers
  • Human granulocyte colony stimulating factor
ECHA InfoCard
100.167.401 Edit this at Wikidata
Chemical and physical data
FormulaC845H1343N223O243S9
Molar mass18802.90 g·mol−1

Filgrastim, sold under the brand name Neupogen among others, is a

under the skin.[13] Filgrastim is a leukocyte growth factor.[12]

Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss.

allergic reactions.[13] It is unclear if use in pregnancy is safe for the baby.[13] Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF).[13] It works by stimulating the body to increase neutrophil production.[13]

Filgrastim was approved for medical use in the United States in 1991.[13] It is on the World Health Organization's List of Essential Medicines.[14][15] Filgrastim biosimilar medications are available.[13]

Medical uses

Filgrastim is used to treat neutropenia;[12] acute myeloid leukemia;[12] nonmyeloid malignancies;[12] leukapheresis;[12] congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia;[12] and myelosuppressive doses of radiation.[12][16]

Tbo-filgrastim (Granix) is

indicated for reduction in the duration of severe neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.[17]

Adverse effects

The most commonly observed adverse effect is mild bone pain after repeated administration,

sickle cell crises, in some cases resulting in death, have been associated with the use of filgrastim in people with sickle cell disorders.[12]

Interactions

Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes; this should be considered when interpreting bone-imaging results.[12]

Mechanism of action

G-CSF is a colony stimulating factor which has been shown to have minimal direct in vivo or in vitro effects on the production of other haematopoietic cell types. Neupogen (filgrastim) is the name for recombinant methionyl human granulocyte colony stimulating factor (r-metHuG-CSF).[12]

Society and culture

Biosimilars

See also:
Biosimilars

In 2015, Sandoz's filgrastim-sndz (trade name Zarxio), obtained the approval of the U.S. Food and Drug Administration (FDA) as a biosimilar.[5][21][22] This was the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), as part of the Affordable Care Act.[5] Zarxio was approved as a biosimilar, not as an interchangeable product, the FDA notes. And under the BPCI Act, only a biologic that has been approved as an "interchangeable" may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA said its approval of Zarxio is based on review of evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Zarxio is biosimilar to Neupogen.[22]

In 2018, filgrastim-aafi (trade name Nivestym) was approved for use in the United States.[23]

In September 2008, Ratiograstim, Tevagrastim, Biograstim, and Filgrastim ratiopharm were approved for use in the European Union.[24][25][26][27] Filgrastim ratiopharm was withdrawn in July 2011 and Biograstim was withdrawn in December 2016.

In February 2009, Filgrastim Hexal and Zarzio were approved for use in the European Union.[28][6]

In June 2010, Nivestim was approved for use in the European Union.[1]

In October 2013, Grastofil was approved for use in the European Union.[29]

In September 2014, Accofil was approved for use in the European Union.[30]

In 2016, Fraven was approved for use by Republic of Turkey ministry of health.[31]

Nivestym was approved for medical use in Canada in April 2020.[2]

In October 2021, Nypozi was approved for medical use in Canada.[3]

Economics

Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia depended upon the clinical situation and the financial model used to pay for treatment.[32] The longer-acting pegfilgrastim may in some cases be more cost-effective.[33]

References

  1. ^ a b c "Nivestim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  2. ^ a b "Summary Basis of Decision (SBD) for Nivestym". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  3. ^ a b "Summary Basis of Decision (SBD) for Nypozi". Health Canada. 23 October 2014. Archived from the original on 25 September 2022. Retrieved 29 May 2022.
  4. ^ a b "Releuko- filgrastim injection, solution". DailyMed. 11 March 2022. Archived from the original on 17 March 2022. Retrieved 16 March 2022.
  5. ^ a b c "FDA approves first biosimilar product Zarxio". U.S. Food and Drug Administration (FDA) (Press release). 6 March 2015. Archived from the original on 11 December 2015. Retrieved 23 November 2015.
  6. ^ a b c "Zarzio EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 October 2019. Retrieved 20 December 2019.
  7. ^ "Filgrastim Use During Pregnancy". Drugs.com. 13 September 2018. Archived from the original on 18 December 2019. Retrieved 17 December 2019.
  8. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
  9. ^ "Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2021. Archived from the original on 1 March 2022. Retrieved 1 March 2022.
  10. ^ "Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 4 July 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  11. ^ "Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  12. ^ a b c d e f g h i j k l m "Neupogen- filgrastim injection, solution". DailyMed. 15 November 2019. Archived from the original on 25 November 2020. Retrieved 20 December 2019.
  13. ^ a b c d e f g h i j k "Filgrastim". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 December 2016.
  14. hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  15. hdl:10665/345533
    . WHO/MHP/HPS/EML/2021.02.
  16. ^ "FDA Approves Radiation Medical Countermeasure". U.S. Food and Drug Administration. 30 March 2015. Retrieved 8 September 2023.
  17. ^ "Granix- tbo-filgrastim injection, solution". DailyMed. 30 November 2019. Retrieved 8 September 2023.
  18. S2CID 33032446
    .
  19. S2CID 2655192
    .
  20. PMID 8450676
    .
  21. ^ "Zarxio (filgrastim-sndz)". U.S. Food and Drug Administration (FDA). 20 April 2015. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  22. ^ a b Tavernise S, Pollack A (6 March 2015). "F.D.A. Approves Zarxio, Its First Biosimilar Drug". The New York Times. Archived from the original on 23 October 2015. Retrieved 23 November 2015.
  23. ^ "Drug Approval Package: Nivestym (filgrastim-aafi)". U.S. Food and Drug Administration (FDA). 21 February 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  24. ^ "Ratiograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 14 August 2020. Retrieved 2 April 2020.
  25. ^ "Tevagrastim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 16 October 2019. Retrieved 2 April 2020.
  26. ^ "Biograstim EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 22 October 2020. Retrieved 2 April 2020.
  27. ^ "Filgrastim ratiopharm EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 21 January 2021. Retrieved 2 April 2020.
  28. ^ "Filgrastim Hexal EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 2 April 2020.
  29. ^ "Grastofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 12 November 2020. Retrieved 2 April 2020.
  30. ^ "Accofil EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 23 March 2020. Retrieved 2 April 2020.
  31. ^ "Arven ilaç, Türkiyenin ilk biyobenzer ürününü üretti" [Arven Pharmaceuticals produced Turkey's first biosimilar product]. Vatan Finans (in Turkish). Archived from the original on 11 February 2023.
  32. S2CID 34894897. {{cite book}}: |journal= ignored (help
    )
  33. OCLC 797824835
    .

Further reading
Retrieved from "https://en.wikipedia.org/w/index.php?title=Filgrastim&oldid=1215622825"